Clinical Trials Browser

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Completed

865 enrolled

Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00616135 2011-05-17

RESTORE-2

Phase 4 Completed

71 enrolled

Breast

Breast Neoplasms, Carcinoma, Neoplasms, Carcinoma, Ductal, Breast

NCT00267553 2007-09-10

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Phase 3 Terminated

200 enrolled

Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Terminated

842 enrolled

Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Clinical Trials

SIGNAL-ER 101

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

RESTORE-2

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer